Clinical Evidence Library
Clinical evidence from guidelines, trials, biomedi…
Long-acting growth hormone in children: what remains uncertain?. Synthesize the consensus and related evidence around which pediatric patients may benefit from long-acting growth hormone and why adherence matters. Separate practical considerations from evidence gaps, especially long-term efficacy, safety, real-world follow-up, and concerns about weekly exposure profiles.
Long-acting growth hormone in children: current consensus and where it fits The current consensus is that long-acting growth hormone (LAGH) is a meaningful once-weekly alternative to daily recombinant human growth hormone for children with growth hormone deficiency, with phase 3 trials showing non-i...
ViewWhen do systematic reviews miss harms?. Narrate why adverse events may be underdetected when reviews rely on randomized trials alone. Explain the need to combine trial data with post-marketing surveillance, spontaneous reports, epidemiology, and unpublished evidence while pre-specifying harms and follow-up.
When systematic reviews of semaglutide or tirzepatide rely on randomized trials alone, they can miss important harms. The trials may include too few people to detect rare adverse events, and they may end before delayed harms appear. Published trial reports can also leave out a lot of adverse event i...
ViewCan AI safely accelerate evidence synthesis?. Build a knowledge-check quiz around what AI tools can and cannot reliably do in systematic review workflows and evidence-disagreement detection. Include items on screening, data extraction, risk-of-bias assessment, human validation, selective reporting, and fine-grained population extraction failures.
Q1. According to the systematic review, which task did AI methods appear to be used for most often in evidence synthesis workflows? - Study screening - Data extraction - Risk-of-bias assessment - Selective reporting detection Answer: Study screening[[cite:1]] Q2. What did the review say about the re...
ViewIs 80 percent medication adherence an evidence-based threshold?. Create a short professional thread that explains the historical 80 percent threshold, the systematic review finding that thresholds vary by condition and outcome, and the limits caused by heterogeneous measures. End with implications for evidence reviewers who need to pre-specify adherence definitions.
Is 80% medication adherence really a universal cutoff? The review says that number came from an early empirical definition in antihypertensive care, where taking at least 80% was treated as sufficient[[cite:1]]. But the authors do not treat 80% as a proven standard. They say they could not reject or...
ViewFive evidence gaps in falls prevention guidelines. Create five cards covering vitamin D, falls education, hip protectors, digital technologies or wearables, and cognitive factors or patient and caregiver involvement. Keep each card evidence-graded and avoid implying that absence or inconsistency equals ineffectiveness.
Vitamin D: mixed and inconsistent guideline recommendations, with several guidelines making no suggestion; this reflects uncertainty, not proven ineffectiveness. Falls education: recommendations were also inconsistent, showing variable guideline endorsement rather than a settled consensus. Hip prote...
ViewHow well do you know the GLP-1 weight-loss evidence?. Design a short educational quiz around comparative efficacy, heterogeneity of treatment effects, gastrointestinal tolerability, absence of head-to-head trials, and limits of long-term evidence. Use answer feedback to reinforce study-design caveats rather than offering clinical advice.
Q1. In the reviewed evidence, which drug generally produced greater average weight loss? - Semaglutide - Tirzepatide - Exenatide - Liraglutide Answer: Tirzepatide[[cite:1]][[cite:2]] Q2. Which study-design issue most strongly limits confidence in the semaglutide versus tirzepatide comparison? - The ...
View- 1(current)